| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/07/2023 | 68.92% | HC Wainwright & Co. | $6 → $5 | Maintains | Buy |
| 10/19/2023 | 102.7% | HC Wainwright & Co. | $17 → $6 | Maintains | Buy |
| 08/17/2023 | 474.32% | HC Wainwright & Co. | → $17 | Reiterates | Buy → Buy |
| 08/04/2023 | 237.84% | Morgan Stanley | $10 → $10 | Reiterates | Equal-Weight → Equal-Weight |
| 08/04/2023 | 68.92% | Barclays | $7 → $5 | Maintains | Equal-Weight |
| 03/17/2023 | 474.32% | HC Wainwright & Co. | $15 → $17 | Maintains | Buy |
| 11/21/2022 | 102.7% | B of A Securities | → $6 | Downgrades | Neutral → Underperform |
| 11/17/2022 | 406.76% | HC Wainwright & Co. | $16 → $15 | Maintains | Buy |
| 11/15/2022 | 237.84% | Morgan Stanley | $11 → $10 | Maintains | Equal-Weight |
| 09/09/2022 | 271.62% | Morgan Stanley | $19 → $11 | Downgrades | Overweight → Equal-Weight |
| 07/29/2022 | 204.05% | Jefferies | → $9 | Initiates Coverage On | → Buy |
| 05/12/2022 | 440.54% | HC Wainwright & Co. | $62 → $16 | Maintains | Buy |
| 03/17/2022 | 541.89% | Morgan Stanley | $20 → $19 | Maintains | Overweight |
| 03/15/2022 | 237.84% | B of A Securities | $50 → $10 | Downgrades | Buy → Neutral |
| 02/28/2022 | 305.41% | Barclays | $20 → $12 | Downgrades | Overweight → Equal-Weight |
| 11/17/2021 | 575.68% | Barclays | $33 → $20 | Maintains | Overweight |
| 10/11/2021 | 1082.43% | Morgan Stanley | $60 → $35 | Upgrades | Equal-Weight → Overweight |
| 10/08/2021 | 1014.86% | Barclays | $80 → $33 | Maintains | Overweight |
| 07/27/2021 | 1927.03% | B of A Securities | → $60 | Upgrades | Neutral → Buy |
| 04/26/2021 | 1994.59% | HC Wainwright & Co. | → $62 | Initiates Coverage On | → Buy |
| 03/17/2021 | 1927.03% | Morgan Stanley | $47 → $60 | Maintains | Equal-Weight |
| 12/16/2020 | 1487.84% | Morgan Stanley | $38 → $47 | Maintains | Equal-Weight |
| 11/12/2020 | 1183.78% | Morgan Stanley | $34 → $38 | Maintains | Equal-Weight |
| 10/20/2020 | 1251.35% | B of A Securities | → $40 | Initiates Coverage On | → Buy |
| 10/20/2020 | 1150% | Goldman Sachs | → $37 | Initiates Coverage On | → Neutral |
| 10/20/2020 | — | Morgan Stanley | Initiates Coverage On | → Equal-Weight |
What is the target price for Prelude Therapeutics (PRLD)?
The latest price target for Prelude Therapeutics (NASDAQ: PRLD) was reported by HC Wainwright & Co. on November 7, 2023. The analyst firm set a price target for $5.00 expecting PRLD to rise to within 12 months (a possible 68.92% upside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Prelude Therapeutics (PRLD)?
The latest analyst rating for Prelude Therapeutics (NASDAQ: PRLD) was provided by HC Wainwright & Co., and Prelude Therapeutics maintained their buy rating.
When is the next analyst rating going to be posted or updated for Prelude Therapeutics (PRLD)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Prelude Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Prelude Therapeutics was filed on November 7, 2023 so you should expect the next rating to be made available sometime around November 7, 2024.
Is the Analyst Rating Prelude Therapeutics (PRLD) correct?
While ratings are subjective and will change, the latest Prelude Therapeutics (PRLD) rating was a maintained with a price target of $6.00 to $5.00. The current price Prelude Therapeutics (PRLD) is trading at is $2.96, which is out of the analyst's predicted range.